Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
November 01 2022 - 6:30AM
Business Wire
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company
leading the way to create a world with better brain health, today
announced the appointment of Laura Gault, MD, Ph.D. as Chief
Medical Officer. In her new role, Dr. Gault will focus on advancing
Sage’s current and emerging product pipeline through all stages of
development.
“We are thrilled to have Dr. Gault join Sage to lead the
development and delivery of our pipeline of potential new medicines
and be a partner in our mission to improve the lives of people
affected by brain health disorders,” said Barry Greene, Chief
Executive Officer at Sage Therapeutics. “Dr. Gault’s vision,
experience and deep commitment to this field of medicine
complements our tremendous sense of urgency to create novel
medicines for people who currently lack adequate treatment
options.”
Dr. Gault brings more than 15 years of pharmaceutical industry
experience advancing programs at early and late stages of
development in rare and common diseases. She has led
multidisciplinary teams focusing in neuropsychiatry,
neuroinflammation and neurodegeneration and has extensive knowledge
of clinical trial design and conduct, and the regulatory landscape
in these areas. In her previous role, Dr. Gault was Vice President,
Therapeutic Area Head for Neurology and Ophthalmology at
Alexion/Astra Zeneca Rare Disease and was responsible for the
development of ravulizumab in generalized myasthenia gravis (gMG)
and neuromyelitis optica spectrum disorder (NMOSD) and the
initiation of new programs in dermatomyositis, Guillain-Barré
syndrome, geographic atrophy and gMG. Prior to that, she held
positions as Vice President, Neurology Clinic Development at Vertex
Pharmaceuticals and Group Project Leader at AbbVie.
Dr. Gault received an M.D. and a Ph.D. in Neuroscience from Case
Western Reserve University and a B.S. in Behavioral Neuroscience
from the University of Pittsburgh. She completed an internship in
Pediatrics, followed by residency in Adult Psychiatry and
fellowship in Child and Adolescent Psychiatry at Yale
University.
“Sage is leading the way in addressing brain health with
purposeful science and a dedicated focus on what matters most to
patients. I’m excited to join this team at a time of incredible
momentum, as the company advances toward important milestones in
its work to evolve the treatment landscape in depression,
neurology, and neuropsychiatry,” said Dr. Gault. “The time to
change how we treat these complex and debilitating disorders is
now, and I look forward to working with my colleagues at Sage to
drive this change.”
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company fearlessly
leading the way to create a world with better brain health. Our
mission is to pioneer solutions to deliver life-changing brain
health medicines, so every person can thrive. For more information,
please visit http://www.sagerx.com.
Forward-Looking Statements
Various statements in this release concern Sage's future
expectations, plans and prospects, including without limitation:
our views and expectations regarding our goals, opportunity, plans,
mission and potential for our products, programs and business.
These statements constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are neither promises nor
guarantees of future performance, and are subject to a variety of
risks and uncertainties, many of which are beyond our control,
which could cause actual results to differ materially from those
contemplated in these forward-looking statements, including the
risks that: the FDA may ultimately decide that the design or
results of our completed, ongoing and planned clinical trials for
any of our product candidates, even if positive, are not sufficient
for regulatory approval in the indications that are the focus of
our development plan; other decisions or actions of the FDA or
other regulatory agencies may affect the regulatory paths for our
product candidates or the initiation, timing, design, size,
progress and cost of clinical trials and our ability to proceed
with further development; success in our earlier clinical trials or
non-clinical studies may not be repeated or observed in ongoing or
future studies, and ongoing and future clinical and non-clinical
results may not meet their primary or key secondary endpoints or
support further development; we may encounter adverse results or
adverse events in use of our products or product candidates that
negatively impact further development or our regulatory or
commercialization plans or that require additional nonclinical and
clinical work which may not yield positive results; the unmet need
for additional treatment options and the potential for our current
or future products, may be significantly smaller than we expect; we
may encounter technical and other unexpected hurdles in the
development and manufacture of our product candidates which may
delay our timing or change our plans or increase our costs; as well
as those risks more fully discussed in the section entitled "Risk
Factors" in our most recent Quarterly Report on Form 10-Q, as well
as discussions of potential risks, uncertainties, and other
important factors in our subsequent filings with the Securities and
Exchange Commission. In addition, any forward-looking statements
represent our views only as of today and should not be relied upon
as representing our views as of any subsequent date. We explicitly
disclaim any obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221031005839/en/
Investors Helen Rubinstein 315-382-3979
helen.rubinstein@sagerx.com Media Matthew Henson
917-930-7147 matthew.henson@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Sep 2023 to Sep 2024